Web Exclusives
Epoetin Alfa Biosimilar Launched at Significant Discount in US
BY KRISTIE ROSA
Frontline Treatment of Metastatic NSCLC Depends on Biomarkers and Histology
BY ANITA T. SHAFFER
Prescribing Patterns of Opiate Use Among Patients with Cancer
BY MINDY WAIZER
FDA Approves Brentuximab Vedotin for Frontline CD30+ Peripheral T-Cell Lymphoma
BY JASON M. BRODERICK
FDA Grants Breakthrough Designation to Brentuximab Vedotin for CD30+ PTCL
BY JASON M. BRODERICK
No Excuses--Talk to Your Patients About Sexuality After Cancer
BY MINDY WAIZER
External Resources
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.